Cumulative incidence of severe (grade 3-4) aGVHD and RFS comparing 7/8 CNI/MTX/abatacept to 8/8 CNI/MTX/placebo. (A) Cumulative incidence of 6-month severe aGVHD by treatment group. 7/8 MMUD with CNI/MTX/abatacept 2.3% (95% CI, 0.2-10.7); 8/8 MUD with CNI/MTX/placebo 14.8% (95% CI, 7.5-24.3). (B) Cumulative incidence of 2-year RFS: 7/8 MMUD with CNI/MTX/abatacept 74.0% (95% CI, 56.3-85.4); 8/8 MUD with CNI/MTX/placebo 60.3% (95% CI, 47.6-70.9). In each panel, red = 7/8 MMUD with CNI/MTX/abatacept; blue = 8/8 MUD with CNI/MTX/placebo.